← Back to Clinical Trials
Recruiting NCT06413069

NCT06413069 Effects of Almonds in Glucose-intolerant Adults (AGAMEMNON)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06413069
Status Recruiting
Phase
Sponsor Charite University, Berlin, Germany
Condition PreDiabetes
Study Type INTERVENTIONAL
Enrollment 150 participants
Start Date 2024-05-23
Primary Completion 2026-04-01

Trial Parameters

Condition PreDiabetes
Sponsor Charite University, Berlin, Germany
Study Type INTERVENTIONAL
Phase N/A
Enrollment 150
Sex ALL
Min Age 35 Years
Max Age 70 Years
Start Date 2024-05-23
Completion 2026-04-01
All Conditions
Interventions
Raw whole almonds

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Tree nuts - such as almonds - contribute to beneficial effects of the Mediterranean diet on risk for cardiovascular events, type 2 diabetes, dyslipidemia, hypertension, inflammation and non-alcoholic fatty liver disease. Almonds provide few carbohydrates, but lots of unsaturated fat and dietary fiber. But to which extent and by which mechanisms may almonds improve all aspects of the Metabolic Syndrome? Previous clinical trials showed weaker effects than rodent studies, most possibly due to low statistical power and metabolically insusceptible patients. The 3-year AGAMEMNON project aims to investigate, if 16 weeks of supplementation with almonds (vs. no treatment) in 150 patients with prediabetes and NAFLD leads to significant improvements in glycemia and liver fat, lipid metabolism, body composition and inflammation. The isocaloric design will outrule effects of weight loss and will allow the analysis of metabolic pathways between fat depots, inflammation, insulin resistance and gut function. Lipidomics are assessed as novel predictor of disease progression and metabolic response.

Eligibility Criteria

Inclusion Criteria: * prediabetes (IFG or IGT or IFG-IGT), measured in plasma samples * NAFLD (MR-S: \>5,56 %) * BMI between 25 and 40 kg/m² Exclusion Criteria: * Treatment with antidiabetic drugs * Overt diabetes mellitus of any kind * Severe cardiovascular or pulmonary disorder * Renal disorder / Renal insufficiency (eGFR \< 60 ml/min/m²) * Severe psychiatric disorder (schizophrenia, severe depression; eating disorders) * Current or recent (\< 5 years) cancer diagnosis * Liver disease other than NAFLD * Use of corticosteroid treatments * Alcohol abuse * Smoking * Ongoing or recently finished (3 months before) weight loss * Current participation in other intervention studies * Pregnancy * Metal implants, claustrophobia * Allergy to almonds

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology